Clinical trials: Sleeping Efficacy
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Chronic Insomnia
Safety and Efficacy of Zolpidem in the Long-Term Treatment of Insomnia
The purpose of this study is to evaluate the safety and efficacy of sublingual zolpidem during the long-term treatment of insomnia.
- Trial name
- NCT05456152
- Testing
- Sublingual Tablet
- Where
- Brazil
- Volunteers
- 358 people
- Sponsor
- EMS
Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep
Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep
This study aims to assess the efficacy of IN 10 003 in improving sleep parameters in patients with Insomnia exhibiting both difficulty in falling asleep and staying asleep.
- Trial name
- NCT01196650
- Testing
- IN 10 003 formulation A, IN 10 003 formulation B
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- Intec Pharma Ltd.
Sleep Initiation and Maintenance Disorders
Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties
The primary objective is to compare the potential for next-day residual effects of volinanserin 2 mg/day and lormetazepam 1 mg/day by measuring the sleepiness in the morning using the patient's sleep questionnaire during 4 weeks…
- Trial name
- REST (NCT00788515)
- Testing
- Volinanserin (M100907), Lormetazepam
- Where
- 3 sites in France, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Primary Insomnia
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
- Trial name
- RESTORA 1 (NCT00608985)
- Testing
- almorexant, zolpidem
- Where
- 91 sites in Australia, Austria and 18 more
- Volunteers
- 709 people
- Sponsor
- Midnight Pharma, LLC
Smoking Cessation, Stress
Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and…
- Conditions
- Smoking Cessation, Stress, Sleep Disturbance, Nausea
- Trial name
- HAVE (NCT04188106)
- Testing
- Varenicline Pill, Hydroxyzine Pill
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Insomnia
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Insomnia is a disorder where people are having trouble sleeping and can include difficulty falling asleep, staying asleep and waking up too early, as well as having unrefreshing sleep.
- Trial name
- NCT03984604
- Testing
- CHI-921
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Canopy Growth Corporation
Restless Legs Syndrome
Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless leg syndrome (RLS).
- Trial name
- NCT00136045
- Testing
- Rotigotine
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- UCB Pharma
Narcolepsy
A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.
- Trial name
- NCT01485770
- Testing
- ADX-N05
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jazz Pharmaceuticals
Obstructive Sleep Apnea, Sleep Apnea
The Comfort of Proactive Sleep Apnea Therapy
The goal of this clinical trial is to compare in OSA patients who regularly adhere to CPAP therapy. The main question[s] it aims to answer are: To assess if proactive therapy can effectively treat OSA with lower mean therapy…
- Trial name
- NCT06144892
- Testing
- Proactive Therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- NovaResp Technologies Inc
Obstructive Sleep Apnea
Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea
A prospective, multi-centre, single-arm, open-label, interventional study with a non-marketed medical device. The primary study objective is to assess the efficacy of the keepMED PAP device on modification of respiratory…
- Trial name
- keePaOSA (NCT04875897)
- Testing
- keepMED PAP device
- Volunteers
- 65 people
- Sponsor
- keepMED Ltd.
Idiopathic Hypersomnia
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in adult participants (ages ≥18 years) with idiopathic hypersomnia (IH).
- Trial name
- NCT07500090
- Testing
- HBS-301 tablet
- Where
- 42 sites in United States, Canada
- Volunteers
- 248 people
- Sponsor
- Harmony Biosciences Management, Inc.
Sleep Bruxism
Efficacy of AesyBite Active in Reducing Sleep Bruxism Activity
The overall objective of the clinical investigation is to evaluate whether the use of the AesyBite Active reduces the bruxism activity.
- Trial name
- NCT06153810
- Testing
- Biofeedback stimulation
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Aesyra SA
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2…
- Trial name
- NCT04549168
- Testing
- Lemborexant
- Where
- 23 sites in China, Taiwan
- Volunteers
- 194 people
- Sponsor
- Eisai Co., Ltd.
Sleep Apnea, Central, Sleep Disordered Breathing
Respicardia, Inc. Pivotal Trial of the remedē System
The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal…
- Conditions
- Sleep Apnea, Central, Sleep Disordered Breathing, Heart Failure
- Trial name
- NCT01816776
- Testing
- Treatment Group (transvenous stimulation of the phrenic nerve), Control Group (Optimal Medical Therapy)
- Where
- 30 sites in United States, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- Respicardia, Inc.
Narcolepsy, Cataplexy Narcolepsy
Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) is a Phase 2, double-blind, randomized, placebo-controlled, crossover, multicenter trial of AXS-12 in patients with narcolepsy.
- Conditions
- Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
- Trial name
- CONCERT (NCT03881852)
- Testing
- AXS-12 (Reboxetine)
- Where
- 14 sites in United States
- Volunteers
- 21 people
- Sponsor
- Axsome Therapeutics, Inc.
Insomnia, Attention Deficit Hyperactivity Disorder
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention…
- Trial name
- NCT00856973
- Testing
- eszopiclone
- Where
- 73 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Narcolepsy
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
- Trial name
- NCT02348593
- Testing
- JZP-110
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals